J
James N. Ingle
Researcher at Mayo Clinic
Publications - 403
Citations - 52917
James N. Ingle is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 82, co-authored 387 publications receiving 47883 citations. Previous affiliations of James N. Ingle include McMaster University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
TL;DR: A genome-wide association study (GWAS) aimed at identifying SNPs associated with MS-AEs was performed and the results of this GWAS and the functional genomic laboratory studies performed have recently been published.
Journal ArticleDOI
Principles of therapy in advanced breast cancer.
TL;DR: An understanding of the importance of certain clinical factors (that is, hormonal receptors, performance score, disease-free interval, sites and extent of metastasis, and tempo of disease) is crucial to the development of the therapeutic plan in the individual patient.
Journal ArticleDOI
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
Kirsten G M Aspros,Jodi M. Carter,Tanya L. Hoskin,Vera J. Suman,Malayannan Subramaniam,Michael J. Emch,Zhenqing Ye,Zhifu Sun,Jason P. Sinnwell,Kevin J. Thompson,Xiaojia Tang,Esther Rodman,Xiyin Wang,Adam W Nelson,Igor Chernukhin,Feda H. Hamdan,Elizabeth S. Bruinsma,Jason S. Carroll,Martin E. Fernandez-Zapico,Steven A. Johnsen,Krishna R. Kalari,Haojie Huang,Roberto A. Leon-Ferre,Fergus J. Couch,James N. Ingle,Matthew P. Goetz,John R. Hawse +26 more
TL;DR: In this paper , the expression profiles of ERβ and its association with clinicopathological features and patient outcomes in the largest cohort of triple negative breast cancer (TNBC) were reported.
Journal ArticleDOI
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
Journal ArticleDOI
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Tanda M. Dudenkov,Duan Liu,Junmei Cairns,Sandhya Devarajan,Yongxian Zhuang,James N. Ingle,Aman U. Buzdar,Mark E. Robson,Michiaki Kubo,Anthony Batzler,Poulami Barman,Gregory D. Jenkins,Erin E. Carlson,Matthew P. Goetz,Donald W. Northfelt,Alvaro Moreno-Aspitia,Zeruesenay Desta,Joel M. Reid,Krishna R. Kalari,Liewei Wang,Richard M. Weinshilboum +20 more
TL;DR: A novel gene encoding an anastrozole transporter, SLC38A7, was identified, as well as epistatic interaction between SNPs in that gene and SNPs near ALPPL2 that influenced both the expression of the transporter and anast rozole plasma concentrations.